{"id":"W2241239684","doi":"10.1200/jco.2007.25.18_suppl.5011","title":"The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Sorafenib; Sunitinib; Renal cell carcinoma; Internal medicine; Expanded access; Chromophobe cell; Adverse effect; Surgery; Clinical trial; Urology; Oncology; Clear cell; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001782068,0.0003972499,0.001019032,0.0002093565,0.0003915711,0.0005596437,0.000324361,0.0003990681,0.003260434],"category_scores_gemma":[0.000996275,0.0002436973,0.0004908983,0.000460014,0.0005806806,0.0003084565,0.0002578055,0.001175461,0.0003241644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009831242,"about_ca_system_score_gemma":0.00263693,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006177713,"about_ca_topic_score_gemma":0.01900966,"domain_scores_codex":[0.9990034,0.000711158,0.00002866431,0.00008546223,0.00009706819,0.0000743035],"domain_scores_gemma":[0.999051,0.0001698605,0.0002041145,0.00005255197,0.000142436,0.0003800283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7784908,0.01724155,0.03591896,0.002307558,0.002243547,0.0004476031,0.0005952597,0.001863166,0.0125869,0.0009330958,0.02643378,0.1209378],"study_design_scores_gemma":[0.7590254,0.1052075,0.1107123,0.0002955285,0.001879985,0.0007066138,0.0002618174,0.002268501,0.001868382,0.0005170668,0.01719834,0.00005863458],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871641,0.00451568,0.000240363,0.001223274,0.00008918606,0.001120589,0.001435687,0.00003608663,0.004174961],"genre_scores_gemma":[0.9898577,0.002732717,0.0006624855,0.0009633093,0.0001876416,0.001335873,0.001854153,0.00001431939,0.002391966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9938223,"threshold_uncertainty_score":0.0122835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1036063042776292,"score_gpt":0.447451878236477,"score_spread":0.3438455739588478,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}